<?xml version="1.0" encoding="utf-8"?>
<html madcap:lastblockdepth="4" madcap:lastheight="878" madcap:lastwidth="701" xmlns:madcap="http://www.madcapsoftware.com/Schemas/MadCap.xsd">
 <head>
 </head>
 <body>
  <h1>
   LEO Pharma UK
  </h1>
  <div style="display: none;">
   <table cellspacing="1" class="TableStyle-dnb_tablestyle_1" style="mc-table-style: url('../Resources/TableStyles/dnb_tablestyle_1.css');">
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <col class="TableStyle-dnb_tablestyle_1-Column-Column1">
    </col>
    <thead>
     <tr class="TableStyle-dnb_tablestyle_1-Head-Header1">
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       DUNS
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadE-Column1-Header1">
       Hoovers ID
      </th>
      <th class="TableStyle-dnb_tablestyle_1-HeadD-Column1-Header1">
       Tier
      </th>
     </tr>
    </thead>
    <tbody>
     <tr class="TableStyle-dnb_tablestyle_1-Body-Body1">
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
        216165753
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyB-Column1-Body1" style="text-align: center;">
       134348
      </td>
      <td class="TableStyle-dnb_tablestyle_1-BodyA-Column1-Body1" style="text-align: center;">
       2
      </td>
     </tr>
    </tbody>
   </table></div><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Synopsis.flsnp" /><p>
   LEO Pharma UK lays claim to being king of the dermatology drug jungle in the UK. As the British arm of Denmark's LEO Pharma, a subsidiary of the privately owned LEO Foundation, the UK unit handles the sales and marketing of LEO Pharma's dermatological and critical care pharmaceutical products in the UK. It has a growing medical department which conducts clinical studies on behalf of the group. Parent LEO Pharma focuses on dermatological disorders, making topical prescription medications for psoriasis and other dermatological conditions. Its lead critical care product is anticoagulant heparin (derived from porcine mucosa). LEO Pharma UK was formed in 1960.
  </p><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Geographic Reach.flsnp" />
  <p>
   LEO Pharma UK markets LEO Pharma's products across the UK. The parent company has locations in 61 countries and operations in more than 100 markets.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Operations.flsnp" />
  <p>
   LEO Pharma UK's medical information team provides support and information to health care professionals and patients regarding its products as well as its compounds in clinical development. The team works closely with colleagues across various divisions and disciplines from sales and marketing to market access and commercial. It also shares its good working practices with international colleagues.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Strategy.flsnp" />
  <p>
   LEO Pharma focuses on research and development, dedicating more than 15% of its annual turnover to R&amp;D. LEO Pharma UK's Regulatory Affairs and Safety teams support LEO Pharma's global discovery, development, and pharmaceutical formulation departments which work in collaboration with more than 400 academic and institutional research centers and industry partners around the world.
  </p>
  <p>
   Growing its business, in 2014 LEO Pharma UK moved its headquarters from Princes Risborough to a new building in Hurley, Berkshire.
  </p>
  <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /><MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/H2 Company Background.flsnp" />
  <p>
   In 2011 the company decided to focus its R&amp;D efforts solely on dermatology and to strengthen its pipeline. To that end, in 2012 it signed a $7 million dollar in-licensing agreement (with additional milestone payments of up to $300 million along with tiered royalty payments) with US biotech company Virobay Inc. to develop an oral treatment for psoriasis.
  </p>
  <p>
   In it efforts to become more patient-centric, LEO Pharma UK introduced a personalized support and guidance program in 2011 to help people who suffer from skin conditions to better manage their conditions.
  </p>
  <p>
   Parent LEO Pharma strives to offer more and improved treatment solutions on a global basis, and in 2009 the company launched a growth strategy to deliver double-digit sales growth through entering new markets and expanding in its existing ones. The US is a strategic focus, as it contributes 20% of total net group sales. The 2012 launch of its
   <company id="144161">
    FDA
   </company>
   -approved Picato gel, a once-daily topical treatment for solar keratoses, also known as actinic keratosis (a potential precursor to non-melanoma skin cancer characterized by thick, scaly, or crusty patches of skin) positioned the company for accelerated growth in the US.
  </p>
  <p>
   LeoaPharma was founded in 1908. It established its UK business in 1960.
  </p>
 <MadCap:snippetBlock src="../Resources/Snippets/Master/Editorial/XML text end.flsnp" /></body>
</html>
